Meta AnalysisID 7149
绝经生殖泌尿综合征的系统证据评价
CRD42023400684
KQ1: What is the effectiveness and harms of screening strategies to identify GSM in postmenopausal women? Does screening impact patient reported symptoms or improve quality of life? KQ2: What is the effectiveness and com
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7149
- Evidence Id
- 15707
- Core Evidence Id
- 15707
- Source Meta Analysis Id
- 7134
- Herb2 Meta Analysis Id
- HBMA007134
- Crd Id
- CRD42023400684
- Title
- A Systematic Evidence Review on Genitourinary Syndrome of Menopause
- Review Question
- KQ1: What is the effectiveness and harms of screening strategies to identify GSM in postmenopausal women? Does screening impact patient reported symptoms or improve quality of life? KQ2: What is the effectiveness and comparative effectiveness of hormonal, non-hormonal, and energy-based interventions when used alone or in combination for treatment of GSM symptoms? Which treatments show improvement for which symptoms? KQ3: What are the harms (and comparative harms) of hormonal, non-hormonal, and energy-based interventions for GSM symptoms? KQ4: What is the appropriate follow-up interval to assess improvement, sustained improvement, or regression of symptoms of GSM in women treated with hormonal, non-hormonal, and energy-based interventions? KQ5: What is the effectiveness, comparative effectiveness, and harms of endometrial surveillance among women who have a uterus and are using hormonal therapy for GSM?
- Study Type Included
- KQ1, 3,&5: RCTs; prospective observational studies with concurrent control group KQ2&4: RCTs
- Condition Being Studied
- Genitourinary Syndrome of Menopause (GSM)
- Participant
- KQ1: Postmenopausal women KQ2-4: Postmenopausal women, premenopausal women in hypoestrogenic state, or gender diverse individuals on hormonal therapy, with one or more symptom of GSM. Excluding individuals with genitourinary symptoms for reasons other than GSM. KQ5: Patients with a uterus using hormonal therapy primarily for GSM symptoms. Excluding patients using hormonal therapy for reasons other than GSM. Excluding: men; children/adolescents; primary indication of endometriosis, dysmenorrhea, polycystic ovarian syndrome, vaginal candidiasis
- Animal
- Human Disease Modelled
- Intervention
- KQ1: Screening evaluations and/or questionnaires. Excluding physical exam. KQ2-4: Hormonal interventions (vaginal estrogen therapy, including vaginal cream, tablets, inserts or ring, ospemifene, intravaginal dehydroepiandrosterone [DHEA], oxytocin vaginal gel, vaginal testosterone; compounded and bioidentical hormonal therapies); Energy-based interventions (CO2 laser, Erbium: YAG, radio-frequency laser); Non-hormonal interventions (over-the-counter non-hormone vaginal lubricants and moisturizers, hyaluronic acid, herbal therapies/supplemental alternatives, phytoestrogens, vitamin D, vitamin E, probiotics, adjuvant, pelvic floor muscle training (PFMT) to treat vaginal or sexual symptoms of GSM) KQ5: Endometrial surveillance (ultrasound or biopsy) Excluding: menopausal hormone therapy if only for reasons other than GSM; laser therapy if for anatomic areas other than the vagina; pelvic floor physical therapy if for urinary incontinence; interventions not available in the U.S. (eg, estriol) and obsolete interventions (eg, 25 mcg estradiol tablets)
- Comparator Control
- KQ1: Usual care KQ2-3: Efficacy (placebo, inactive control, sham); Comparative Effectiveness (another hormonal, non-hormonal, or energy-based intervention) KQ4: Different durations of follow-up KQ5: Usual care; different type or level of surveillance
- Main Outcome
- KQ1: Diagnosis of GSM, misdiagnosis as another condition, progressing to unnecessary diagnostics (eg, vaginal or endometrial biopsy) KQ2&4: Change in most bothersome symptom(s) - Self-reported or clinician assessed - Genitourinary symptoms (ie, distress, bother or interference of genitourinary symptoms) - Other urinary symptoms (eg, discomfort or pain when urinating, overactive bladder, urge urinary incontinence) - Genital symptoms (eg, vulvovaginal dryness, vulvovaginal discomfort or irritation) - Sexual symptoms (eg, pain with sex, sexual function, sexual desire) - Psychological symptoms (eg, quality of life, depression, anxiety) KQ3&5: Safety, (systemic) adverse events, side effects of treatment - Self-reported or clinician assessed KQ5: Endometrial hyperplasia, endometrial cancer, post-menopausal bleeding Measures of effect Any
- Outcome Measure
- Additional Outcome
- None Measures of effect Not applicable
- Study Method
- Systematic review
- Keyword
- Humans
- Contact
- Catherine Sowerby [email protected]
- Organisational Affiliation
- Minneapolis VA
- Funding Source
- This project was funded under Contract No. 75Q80120D00008 from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services Grant number(s) State the funder, grant or award number and the date of award Contract No. 75Q80120D00008
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-02-28
- Registration Date
- 2023-03-11
- Anticipated Start Date
- 2022-12-30
- Anticipated Completion Date
- 2024-01-12
- Title Cn
- 绝经生殖泌尿综合征的系统证据评价
- Title En
- A Systematic Evidence Review on Genitourinary Syndrome of Menopause
- Bilingual Status
- complete